Evidence map›Paper›PMID 34273152›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.

Yubing Tao, Fei Wang, Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo and 16 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Expression of WNT10A in papillary thyroid carcinoma and its effect on cell proliferation, invasion, and metastasis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 13 institutions in 7 countries.

Yubing TaoDepartment of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
Fei WangDepartment of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaopei ShenLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Guangwu ZhuLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rengyun LiuLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David ViolaEndocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Rossella EliseiEndocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Efisio PuxedduDepartment of Medicine, University of Perugia, Perugia, Italy.
Laura FugazzolaDivision of Endocrinology and Metabolism, IRCCS Istituto Auxologico Italiano, Milan and Department of Pathophysiology and Transplantation, University of Milan, Italy.
Carla ColomboDivision of Endocrinology and Metabolism, IRCCS Istituto Auxologico Italiano, Milan and Department of Pathophysiology and Transplantation, University of Milan, Italy.
Barbara JarzabMaria Sklodowska-Curie National Institute of Oncology, Gliwice Branch, Gliwice,Poland.
Agnieszka CzarnieckaMaria Sklodowska-Curie National Institute of Oncology, Gliwice Branch, Gliwice,Poland.
Alfred K LamCancer Molecular Pathology of School of Medicine, Griffith University-Gold Coast, Australia.
Caterina MianDepartment of Medicine, Endocrinology Unit, University of Padua, Padua, Italy.
Federica VianelloVeneto Institute of Oncology, IRCCS, Padua, Italy.
Linwah YipUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Garcilaso Riesco-EizaguirreDepartment of Endocrinology and Nutrition Hospital Universitario La Paz and Hospital Universitario de Móstoles, Madrid, Spain.
Pilar SantistebanBiomedical Research Institute "Alberto Sols," Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain.
Christine J O'NeillEndocrine Surgical Unit, University of Sydney, Sydney, Australia.
Mark S SywakEndocrine Surgical Unit, University of Sydney, Sydney, Australia.
Roderick Clifton-BlighEndocrine Surgical Unit, University of Sydney, Sydney, Australia.
Bela BendlovaDepartment of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
Vlasta SýkorováDepartment of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
Shihua ZhaoDepartment of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
Yangang WangDepartment of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
Mingzhao XingLaboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4797-610X
Johns Hopkins University · USQingdao University · CNThe University of Sydney · AUConsejo Superior de Investigaciones Científicas · ESInstitute of Endocrinology · CZThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Milan · ITUniversity of Pisa · ITGriffith University · AUIstituto Oncologico Veneto · ITUniversity of Padua · ITUniversity of Perugia · ITUniversity of Pittsburgh · US

Funding

Older Age and BRAF-positivity as Risk Modifiers for Papillary Thyroid CancerR03AG042334 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIP, LIN · 2012 to 2013
$148k
NIA NIH HHS R03 AG042334NIH HHS 5R03AG042334-02
6 · The paper itself

Abstract

contextHow lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined.

objectiveTo study whether BRAF V600E affected LNM-associated mortality in PTC. DESIGN, SETTING, AND

participantsWe retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 [interquartile range (IQR) 35-58] years and median follow-up time of 58 (IQR 26-107) months.

resultsOverall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAF V600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAF V600E patients; mortality rates were 2/659 (0.3%) vs 4/321 (1.2%) in non-LNM vs LNM patients (P = 0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAF V600E CPTC, morality rates were 7/515 (1.4%) vs 28/363 (7.7%) in non-LNM vs LNM patients (P < 0.001), corresponding to an HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAF V600E vs absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism.

conclusionsLNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance.

Indexed as

MutationAdultBiomarkers, TumorFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins B-rafRetrospective StudiesSurvival RateThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafBRAF mutationlymph node metastasismortalityprognostic molecular markerrisk stratificationthyroid cancer

Identifiers

PMID34273152
PMCPMC8530728
OpenAlexW3183634611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.